← Eichor
Condition: Exudative Macular Degeneration Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Exudative Macular Degeneration

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Phase 4 · 1 location(s) · Medical University of Vienna · NCT05093374MMP-9 Inhibition for Recalcitrant Wet AMD
Phase 2 · 1 location(s) · University of Iowa · NCT04504123Progression of Early Atrophic Lesions
Phase N/A · 1 location(s) · University of Utah · NCT05959005Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degener
Phase N/A · 1 location(s) · Saglik Bilimleri Universitesi · NCT07235527A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Phase 2/Phase 3 · 91 location(s) · EyeBiotech Ltd. · NCT07440225Ethical Issues of Using Gene Therapy in the Treatment of AMD
Phase N/A · 1 location(s) · Nantes University Hospital · NCT07004361Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
Phase N/A · 1 location(s) · AI-Spectral · NCT07446582Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
Phase N/A · 1 location(s) · Nantes University Hospital · NCT06271330Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Phase 1 · 7 location(s) · Caregen Co. Ltd. · NCT06132035Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · 181 location(s) · AbbVie · NCT05407636Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macul
Phase 3 · 94 location(s) · 4D Molecular Therapeutics · NCT07064759Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to E
Phase 3 · 36 location(s) · King's College Hospital NHS Trust · NCT04663750A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Phase 2/Phase 3 · 63 location(s) · EyeBiotech Ltd. · NCT07496567Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degenerati
Phase N/A · 1 location(s) · Nantes University Hospital · NCT074234294D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/Phase 2 · 25 location(s) · 4D Molecular Therapeutics · NCT05197270EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Labe
Phase N/A · 1 location(s) · Insel Gruppe AG, University Hospital Bern · NCT07434713Stem Cell Ophthalmology Treatment Study II
NA · 4 location(s) · MD Stem Cells · NCT03011541
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.